Английская Википедия:Chloroquine

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Distinguish Шаблон:Use dmy dates Шаблон:Cs1 config Шаблон:Infobox drug

Chloroquine is a medication primarily used to prevent and treat malaria in areas where malaria remains sensitive to its effects.[1] Certain types of malaria, resistant strains, and complicated cases typically require different or additional medication.[1] Chloroquine is also occasionally used for amebiasis that is occurring outside the intestines, rheumatoid arthritis, and lupus erythematosus.[1] While it has not been formally studied in pregnancy, it appears safe.[1][2] It was studied to treat COVID-19 early in the pandemic, but these studies were largely halted in the summer of 2020, and the NIH does not recommend its use for this purpose.[3] It is taken by mouth.[1]

Common side effects include muscle problems, loss of appetite, diarrhea, and skin rash.[1] Serious side effects include problems with vision, muscle damage, seizures, and low blood cell levels.[1][4] Chloroquine is a member of the drug class 4-aminoquinoline.[1] As an antimalarial, it works against the asexual form of the malaria parasite in the stage of its life cycle within the red blood cell.[1] How it works in rheumatoid arthritis and lupus erythematosus is unclear.[1]

Chloroquine was discovered in 1934 by Hans Andersag.[5][6] It is on the World Health Organization's List of Essential Medicines.[7] It is available as a generic medication.[1]

Шаблон:TOC limit

Medical uses

Malaria

Файл:Paludisme.png
Distribution of malaria in the world:[8]
 Elevated occurrence of chloroquine- or multi-resistant malaria
 Occurrence of chloroquine-resistant malaria
 No Plasmodium falciparum or chloroquine-resistance
 No malaria

Chloroquine has been used in the treatment and prevention of malaria from Plasmodium vivax, P. ovale, and P. malariae. It is generally not used for Plasmodium falciparum as there is widespread resistance to it.[9][10]

Chloroquine has been extensively used in mass drug administrations, which may have contributed to the emergence and spread of resistance. It is recommended to check if chloroquine is still effective in the region prior to using it.[11] In areas where resistance is present, other antimalarials, such as mefloquine or atovaquone, may be used instead. The Centers for Disease Control and Prevention recommend against treatment of malaria with chloroquine alone due to more effective combinations.[12]

Amebiasis

In treatment of amoebic liver abscess, chloroquine may be used instead of or in addition to other medications in the event of failure of improvement with metronidazole or another nitroimidazole within five days or intolerance to metronidazole or a nitroimidazole.[13]

Rheumatic disease

As it mildly suppresses the immune system, chloroquine is used in some autoimmune disorders, such as rheumatoid arthritis and has an off label indication for lupus erythematosus.[1]

Side effects

Side effects include blurred vision, nausea, vomiting, abdominal cramps, headache, diarrhea, swelling legs/ankles, shortness of breath, pale lips/nails/skin, muscle weakness, easy bruising/bleeding, hearing and mental problems.[14][15]

  • Unwanted/uncontrolled movements (including tongue and face twitching)[14]
  • Deafness or tinnitus.[14]
  • Nausea, vomiting, diarrhea, abdominal cramps.[15]
  • Headache.[14]
  • Mental/mood changes (such as confusion, personality changes, unusual thoughts/behavior, depression, feeling being watched, hallucinating)[14][15]
  • Signs of serious infection (such as high fever, severe chills, persistent sore throat)[14]
  • Skin itchiness, skin color changes, hair loss, and skin rashes.[15][16]
    • Chloroquine-induced itching is very common among black Africans (70%), but much less common in other races. It increases with age, and is so severe as to stop compliance with drug therapy. It is increased during malaria fever; its severity is correlated to the malaria parasite load in blood. Some evidence indicates it has a genetic basis and is related to chloroquine action with opiate receptors centrally or peripherally.[17]
  • Unpleasant metallic taste
    • This could be avoided by "taste-masked and controlled release" formulations such as multiple emulsions.[18]
  • Chloroquine retinopathy
  • Electrocardiographic changes[19]
    • This manifests itself as either conduction disturbances (bundle-branch block, atrioventricular block) or Cardiomyopathy – often with hypertrophy, restrictive physiology, and congestive heart failure. The changes may be irreversible. Only two cases have been reported requiring heart transplantation, suggesting this particular risk is very low. Electron microscopy of cardiac biopsies show pathognomonic cytoplasmic inclusion bodies.
  • Pancytopenia, aplastic anemia, reversible agranulocytosis, low blood platelets, neutropenia.[20]

Pregnancy

Chloroquine has not been shown to have any harmful effects on the fetus when used in the recommended doses for malarial prophylaxis.[21] Small amounts of chloroquine are excreted in the breast milk of lactating women. However, this drug can be safely prescribed to infants, the effects are not harmful. Studies with mice show that radioactively tagged chloroquine passed through the placenta rapidly and accumulated in the fetal eyes which remained present five months after the drug was cleared from the rest of the body.[20][22] Women who are pregnant or planning on getting pregnant are still advised against traveling to malaria-risk regions.[21]

Elderly

There is not enough evidence to determine whether chloroquine is safe to be given to people aged 65 and older. Since it is cleared by the kidneys, toxicity should be monitored carefully in people with poor kidney functions.[20]

Drug interactions

Chloroquine has a number of drug–drug interactions that might be of clinical concern:Шаблон:Citation needed

Overdose

Chloroquine, in overdose, has a risk of death of about 20%.[23] It is rapidly absorbed from the gut with an onset of symptoms generally within an hour.[24] Symptoms of overdose may include sleepiness, vision changes, seizures, stopping of breathing, and heart problems such as ventricular fibrillation and low blood pressure.[23][24] Low blood potassium may also occur.[23]

While the usual dose of chloroquine used in treatment is 10 mg/kg, toxicity begins to occur at 20 mg/kg, and death may occur at 30 mg/kg.[23] In children as little as a single tablet can cause problems.[24]

Treatment recommendations include early mechanical ventilation, cardiac monitoring, and activated charcoal.[23] Intravenous fluids and vasopressors may be required with epinephrine being the vasopressor of choice.[23] Seizures may be treated with benzodiazepines.[23] Intravenous potassium chloride may be required, however this may result in high blood potassium later in the course of the disease.[23] Dialysis has not been found to be useful.[23]

Pharmacology

Absorption of chloroquine is rapid and primarily happens in the gastrointestinal tract.[25] It is widely distributed in body tissues.[26] Protein binding in plasma ranges from 46% to 79%.[27] Its metabolism is partially hepatic, giving rise to its main metabolite, desethylchloroquine.[28] Its excretion is ≥50% as unchanged drug in urine, where acidification of urine increases its elimination.Шаблон:Citation needed It has a very high volume of distribution, as it diffuses into the body's adipose tissue.Шаблон:Citation needed

Accumulation of the drug may result in deposits that can lead to blurred vision and blindness.[29] It and related quinines have been associated with cases of retinal toxicity, particularly when provided at higher doses for longer times.Шаблон:Citation needed With long-term doses, routine visits to an ophthalmologist are recommended.Шаблон:Citation needed

Chloroquine is also a lysosomotropic agent, meaning it accumulates preferentially in the lysosomes of cells in the body.Шаблон:Citation needed The pKa for the quinoline nitrogen of chloroquine is 8.5, meaning it is about 10% deprotonated at physiological pH (per the Henderson-Hasselbalch equation).Шаблон:Citation needed This decreases to about 0.2% at a lysosomal pH of 4.6.Шаблон:Citation needed Because the deprotonated form is more membrane-permeable than the protonated form, a quantitative "trapping" of the compound in lysosomes results.Шаблон:Citation needed

Mechanism of action

Файл:Medical quinolines pathway.png
Medical quinolines

Malaria

Файл:Birefringence of malaria pigment.jpg
Hemozoin formation in P. falciparum: many antimalarials are strong inhibitors of hemozoin crystal growth.

The lysosomotropic character of chloroquine is believed to account for much of its antimalarial activity; the drug concentrates in the acidic food vacuole of the parasite and interferes with essential processes. Its lysosomotropic properties further allow for its use for in vitro experiments pertaining to intracellular lipid related diseases,[30][31] autophagy, and apoptosis.[32]

Inside red blood cells, the malarial parasite, which is then in its asexual lifecycle stage, must degrade hemoglobin to acquire essential amino acids, which the parasite requires to construct its own protein and for energy metabolism. Digestion is carried out in a vacuole of the parasitic cell.Шаблон:Citation needed

Hemoglobin is composed of a protein unit (digested by the parasite) and a heme unit (not used by the parasite). During this process, the parasite releases the toxic and soluble molecule heme. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP). To avoid destruction by this molecule, the parasite biocrystallizes heme to form hemozoin, a nontoxic molecule. Hemozoin collects in the digestive vacuole as insoluble crystals.Шаблон:Citation needed

Chloroquine enters the red blood cell by simple diffusion, inhibiting the parasite cell and digestive vacuole. Chloroquine (CQ) then becomes protonated (to CQ2+), as the digestive vacuole is known to be acidic (pH 4.7); chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further biocrystallization of heme, thus leading to heme buildup. Chloroquine binds to heme (or FP) to form the FP-chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion.[33] Parasites that do not form hemozoin are therefore resistant to chloroquine.[34]

Resistance in malaria

Since the first documentation of P. falciparum chloroquine resistance in the 1950s, resistant strains have appeared throughout East and West Africa, Southeast Asia, and South America. The effectiveness of chloroquine against P. falciparum has declined as resistant strains of the parasite evolved.

Resistant parasites are able to rapidly remove chloroquine from the digestive vacuole using a transmembrane pump. Chloroquine-resistant parasites pump chloroquine out at 40 times the rate of chloroquine-sensitive parasites; the pump is coded by the P. falciparum chloroquine resistance transporter (PfCRT) gene.[35] The natural function of the chloroquine pump is to transport peptides: mutations to the pump that allow it to pump chloroquine out impairs its function as a peptide pump and comes at a cost to the parasite, making it less fit.[36]

Resistant parasites also frequently have mutation in the ABC transporter P. falciparum multidrug resistance (PfMDR1) gene, although these mutations are thought to be of secondary importance compared to PfCRT. An altered chloroquine-transporter protein, CG2 has been associated with chloroquine resistance, but other mechanisms of resistance also appear to be involved.[37]

Verapamil, a Ca2+ channel blocker, has been found to restore both the chloroquine concentration ability and sensitivity to this drug. Other agents which have been shown to reverse chloroquine resistance in malaria are chlorpheniramine, gefitinib, imatinib, tariquidar and zosuquidar.[38]

Шаблон:As of chloroquine is still effective against poultry malaria in Thailand. Sohsuebngarm et al. 2014 test P. gallinaceum at Chulalongkorn University and find the parasite is not resistant.[39]Шаблон:Rp Sertraline, fluoxetine and paroxetine reverse chloroquine resistance, making resistant biotypes susceptible if used in a cotreatment.[40]

Antiviral

Chloroquine has antiviral effects against some viruses.[41] It increases late endosomal and lysosomal pH, resulting in impaired release of the virus from the endosome or lysosome – release of the virus requires a low pH. The virus is therefore unable to release its genetic material into the cell and replicate.[42][43]

Chloroquine also seems to act as a zinc ionophore that allows extracellular zinc to enter the cell and inhibit viral RNA-dependent RNA polymerase.[44][45]

Other

Chloroquine inhibits thiamine uptake.[46] It acts specifically on the transporter SLC19A3.

Against rheumatoid arthritis, it operates by inhibiting lymphocyte proliferation, phospholipase A2, antigen presentation in dendritic cells, release of enzymes from lysosomes, release of reactive oxygen species from macrophages, and production of IL-1.

History

In Peru, the indigenous people extracted the bark of the Cinchona tree (Cinchona officinalis)[47] and used the extract to fight chills and fever in the seventeenth century. In 1633, this herbal medicine was introduced in Europe, where it was given the same use and also began to be used against malaria. The quinoline antimalarial drug quinine was isolated from the extract in 1820.[48]Шаблон:Rp

After World War I, the German government sought alternatives to quinine. Chloroquine, a synthetic analogue with the same mechanism of action was discovered in 1934, by Hans Andersag and coworkers at the Bayer laboratories, who named it Resochin.[49][50] It was ignored for a decade, because it was considered too toxic for human use. Instead, in World War II, the German Africa Corps used the chloroquine analogue 3-methyl-chloroquine, known as Sontochin. After Allied forces arrived in Tunis, Sontochin fell into the hands of Americans, who sent the material back to the United States for analysis, leading to renewed interest in chloroquine.[51][52] United States government-sponsored clinical trials for antimalarial drug development showed unequivocally that chloroquine has a significant therapeutic value as an antimalarial drug.[48]Шаблон:Rp It was introduced into clinical practice in 1947 for the prophylactic treatment of malaria.[53]

Chemical synthesis

The first synthesis of chloroquine was disclosed in a patent filed by IG Farben in 1937.[54] In the final step, 4,7-dichloroquinoline was reacted with 1-diethylamino-4-aminopentane.

Файл:Chloroquin Synthese.svg

By 1949, chloroquine manufacturing processes had been established to allow its widespread use.[55]

Society and culture

Файл:Esochin® Tabletten (Rückseite).jpg
Resochin tablet package

Formulations

Chloroquine comes in tablet form as the phosphate, sulfate, and hydrochloride salts. Chloroquine is usually dispensed as the phosphate.[56]

Names

Brand names include Chloroquine FNA, Resochin, Dawaquin, and Lariago.[57]

Other animals

Chloroquine, in various chemical forms, is used to treat and control surface growth of anemones and algae, and many protozoan infections in aquariums,[58] e.g. the fish parasite Amyloodinium ocellatum.[59] It is also used in poultry malaria.[39]Шаблон:Rp

Research

Chloroquine was proposed as a treatment for SARS, with in vitro tests inhibiting the severe acute respiratory syndrome coronavirus (SARS-CoV).[60][61] In October 2004, a published report stated that chloroquine acts as an effective inhibitor of the replication of SARS-CoV in vitro.[60] In August 2005, a peer-reviewed study confirmed and expanded upon the results.[62]

Chloroquine was being considered in 2003, in pre-clinical models as a potential agent against chikungunya fever.[63]

COVID-19

Шаблон:Excerpt

Other

The radiosensitizing and chemosensitizing properties of chloroquine are being evaluated for anticancer strategies in humans.[64][65] In biomedicinal science, chloroquine is used for in vitro experiments to inhibit lysosomal degradation of protein products. Chloroquine and its modified forms have also been evaluated as treatment options for inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease.[66]

References

Шаблон:Reflist

External links

Шаблон:Scholia Шаблон:Commons category

Шаблон:Chromalveolate antiparasitics Шаблон:Antirheumatic products Шаблон:Glutamate metabolism and transport modulators Шаблон:Portal bar Шаблон:Authority control

  1. 1,00 1,01 1,02 1,03 1,04 1,05 1,06 1,07 1,08 1,09 1,10 1,11 Шаблон:Cite web
  2. Шаблон:Cite web
  3. Шаблон:Cite web
  4. Шаблон:Cite book
  5. Шаблон:Cite book
  6. Шаблон:Cite book
  7. Шаблон:Cite book
  8. Шаблон:Cite web
  9. Шаблон:Cite book
  10. Шаблон:Cite book
  11. Шаблон:Cite web
  12. CDC. Health information for international travel 2001–2002. Atlanta, Georgia: U.S. Department of Health and Human Services, Public Health Service, 2001.
  13. Шаблон:EMedicine
  14. 14,0 14,1 14,2 14,3 14,4 14,5 Шаблон:Cite web
  15. 15,0 15,1 15,2 15,3 Шаблон:Cite web
  16. Шаблон:Cite web
  17. Шаблон:Cite journal
  18. Шаблон:Cite journal
  19. Шаблон:Cite journal
  20. 20,0 20,1 20,2 20,3 20,4 20,5 20,6 20,7 Шаблон:Cite web
  21. 21,0 21,1 Шаблон:Cite web
  22. Шаблон:Cite journal
  23. 23,0 23,1 23,2 23,3 23,4 23,5 23,6 23,7 23,8 Шаблон:Cite journal
  24. 24,0 24,1 24,2 Шаблон:Cite journal
  25. Шаблон:Cite web
  26. Шаблон:Cite journal
  27. Шаблон:Cite journal
  28. Шаблон:Cite journal
  29. Шаблон:Cite journal
  30. Шаблон:Cite journal
  31. Шаблон:Cite journal
  32. Шаблон:Cite journal
  33. Шаблон:Cite journal
  34. Шаблон:Cite journal
  35. Шаблон:Cite journal
  36. Шаблон:Cite journal
  37. Шаблон:Cite book
  38. Шаблон:Cite journal
  39. 39,0 39,1 Шаблон:Cite book
  40. Шаблон:Cite journal
  41. Шаблон:Cite journal
  42. Шаблон:Cite journal
  43. Шаблон:Cite journal
  44. Шаблон:Cite journal
  45. Шаблон:Cite journal
  46. Шаблон:Cite journal
  47. Шаблон:Cite web
  48. 48,0 48,1 Шаблон:Cite book
  49. Шаблон:Cite journal
  50. Шаблон:Cite journal
  51. Шаблон:Cite book
  52. Шаблон:Cite journal
  53. Шаблон:Cite web
  54. Шаблон:Cite patent
  55. Шаблон:Cite journal
  56. Шаблон:Cite web
  57. Шаблон:Cite web
  58. Шаблон:Cite web
  59. Шаблон:Cite web
  60. 60,0 60,1 Шаблон:Cite journal
  61. Шаблон:Cite journal
  62. Шаблон:Cite journal
  63. Шаблон:Cite journal
  64. Шаблон:Cite journal
  65. Шаблон:Cite journal
    Шаблон:Cite journal
  66. Шаблон:Cite book